Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12490673 | 0.80 | NPC1 (0.61) | TSHRCA1CA2RAB9AMAPT | |
| SCHEMBL11746674 | 0.80 | SLC18A3 (0.57) | MAPTGRM1SLC18A3 | |
| SCHEMBL11900371 | 0.76 | SRD5A2 (0.57) | CA1CA2RAB9AMAPTTDP1 | |
| SCHEMBL2349726 | 0.76 | NPC1 (0.70) | TSHRCA1CA2RAB9AMAPT | |
| SCHEMBL857083 | 0.74 | KMT2A (0.54) | TSHRRAB9AMAPTALDH1A1MEN1 | |
| SCHEMBL29519648 | 0.74 | KMT2A (0.54) | TSHRRAB9AMAPTALDH1A1MEN1 | |
| Methyl Benzoate SCHEMBL28249321 | 0.73 | TSHR (0.95) | TSHRCA1CA2RAB9AMAPT | |
| SCHEMBL13944265 | 0.73 | MEN1 (0.66) | TSHRCA1CA2RAB9AMAPT | |
| SCHEMBL11900436 | 0.73 | ALDH1A1 (0.53) | TSHRCA1CA2RAB9AMAPT | |
| Benzene SCHEMBL28351738 | 0.73 | TSHR (0.85) | TSHRCA1CA2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7595343-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2009-09-29 | — | — | US | disclosed |
| US-20060058298-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20050288282-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1590340-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2005-11-02 | — | — | EP | disclosed |
| US-6897220-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2005-05-24 | — | — | US | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| US-20040142953-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2004-07-22 | — | — | US | disclosed |
| EP-1429765-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| US-20040106599-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2004-06-03 | — | — | US | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288282-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | TSHR 3869/4885CA1 1896/4885CA2 1712/4885 |
| US-20040106599-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | TSHR 3869/4885CA1 1896/4885CA2 1712/4885 |
| US-20060058298-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | TSHR 3869/4885CA1 1896/4885CA2 1712/4885 |
| US-20040142953-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | TSHR 3869/4885CA1 1896/4885CA2 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.